Alkermes plc (NASDAQ:ALKS) Q3 2025 Earnings Call Transcript
Operator: Greetings, and welcome to Alkermes' Third Quarter 2025 Financial Results Conference Call. My name is Rob, and I'll be your operator for today's call.
Alkermes Plc. (ALKS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.31 | 35,000 | $815,734.50 | 80,000 | 2022-11-14 | Filing | |
| $23.43 | 427 | $10,004.61 | 9,366 | 2022-03-04 | Filing | |
| $30.22 | 1,650 | $49,860.40 | 1,650 | 2021-08-23 | Filing | |
| $26.43 | 10,000 | $264,269.00 | 10,000 | 2021-08-02 | Filing | |
| $19.65 | 6,940 | $136,371.00 | 11,242 | 2020-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.53 | 9,000 | $283,776.30 | 73,740 | 2025-10-15 | Filing | |
| $31.09 | 3,334 | $103,654.06 | 86,208 | 2025-06-10 | Filing | |
| $31.95 | 3,333 | $106,489.35 | 89,542 | 2025-06-09 | Filing | |
| $34.00 | 1,938 | $65,892.00 | 7,717 | 2025-02-28 | Filing | |
| $35.26 | 3,743 | $131,978.18 | 7,717 | 2025-02-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 901,333 | $27,039,990 | 0.18% | |
| 2. | 808,132 | $24,243,960 | 0.06% | |
| 3. | 533,650 | $16,009,500 | 0.02% | |
| 4. | 385,342 | $11,560,260 | 0.63% | |
| 5. | 257,795 | $7,733,850 | 0.23% |
News See All
HC Wainwright Affirms Alkermes (ALKS) ‘Neutral’ Rating on Vibrance-1 Phase 2 Study
Alkermes (NASDAQ:ALKS) is one of the best beginner stocks to buy, according to analysts. On September 9, HC Wainwright reiterated a ‘Neutral’ rating on the stock and a $46 price target.
12 Best Beginner Stocks to Buy According to Analysts
Stronger-than-expected corporate profits and the prospect of the US Federal Reserve cutting interest rates are the catalysts likely to push equity markets higher.
Alkermes plc (ALKS) Completes Enrollment in Key Narcolepsy Trial, Data Due Q3 2025
Alkermes plc (NASDAQ:ALKS) tops our list for being one of the best psychedelic stocks. It is an Ireland-based biopharmaceutical company with U.S.
13 Best Psychedelic Stocks to Invest in Now
Unlike drugs such as cocaine or marijuana, psychedelics create an “alternate reality” by altering feelings, thoughts, and energy levels.
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Alkermes Second Quarter 2025 Financial Results Conference Call. My name is Rob, and I'll be your operator for today's call. [Operator Instructions].
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia
Alkermes plc (NASDAQ:ALKS) is a global biopharmaceutical company headquartered in Ireland, with U.S.
10 Most Undervalued Pharma Stocks to Buy Now
Pharmaceutical manufacturing in the U.S. has declined sharply over recent decades, with most active ingredient production shifting overseas due to lower labor costs. In 2023, the U.S.
Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating
Alkermes plc (NASDAQ:ALKS) is one of the high-margin pharma stocks to buy now.
10 Best High-Margin Pharma Stocks to Buy Now
The pharmaceutical sector continues to stand out as a resilient and highly profitable corner of the market, even amid global economic uncertainty.
Hedge Fund Resource Center Billionaire Hedge Funds
